首页> 美国卫生研究院文献>Journal of Clinical Medicine >Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience
【2h】

Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience

机译:使用他拉泊芬钠进行食管癌放化疗或放疗后局部衰竭的光动力疗法:单中心经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A phase II study of second-generation photodynamic therapy (PDT) using talaporfin sodium has shown excellent treatment results for esophageal cancer with local failure after chemoradiotherapy (CRT) or radiotherapy (RT). However, only a few studies have reported this therapy in clinical practice. This study aimed to confirm the efficacy and safety of salvage PDT using talaporfin sodium for esophageal cancer in various clinical situations. Twelve patients with esophageal cancer with local failure after definitive CRT or RT who underwent PDT using talaporfin sodium were enrolled from April 2016 to January 2020. Overall, 10 patients (83.3%) achieved a local complete response. No skin phototoxicity was observed, but esophageal stricture occurred in five patients (41.7%). Esophageal stricture was improved with endoscopic balloon dilation in all patients, and subsequent analysis found no significant factors causing esophageal stricture after PDT. Two patients with synchronous tumors were successfully rescued by combination therapy with endoscopic submucosal dissection. Two patients with carcinoma in situ of larger than 1/2 circumference were rescued by repeated PDT. The 2-year overall survival was 80.0% (95% confidence interval 0.409–0.946). PDT using talaporfin sodium was an effective and safe salvage treatment for esophageal cancer with local failure after CRT or RT in various clinical situations.
机译:使用他拉泊芬钠进行的第二代光动力疗法(PDT)的II期研究显示,放化疗(CRT)或放疗(RT)后局部失败的食管癌疗效优异。但是,只有少数研究在临床实践中报告了这种疗法。这项研究旨在证实在不同的临床情况下,使用他拉泊芬钠治疗食管癌的PDT疗效和安全性。自2016年4月至2020年1月,共入选了12例经确诊CRT或放疗后局部放疗失败的食管癌患者,使用talaporfin钠进行了PDT。总共有10例患者(占83.3%)达到了局部完全缓解。没有观察到皮肤光毒性,但是五名患者(41.7%)发生了食道狭窄。内镜下球囊扩张术可改善所有患者的食管狭窄,随后的分析发现,PDT后没有引起食管狭窄的重要因素。内镜下黏膜下剥离联合治疗成功治愈了两名同步肿瘤患者。重复PDT救治了两名原位癌大于1/2周长的原位癌。 2年总生存率为80.0%(95%置信区间0.409-0.946)。使用他拉泊芬钠的PDT在各种临床情况下,对于CRT或RT后局部失败的食管癌是一种有效而安全的挽救方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号